INOVIO receives Orphan Drug Designation for INO-3107 to treat Recurrent Respiratory Papillomatosis

Last year, VIO published data from its pilot clinical study of -3106 (DNA medicine candidate targeting HPV 6-caused RRP) in the scientific journal Vaccines (MDPI). Study results demonstrated that -3106 generated immunogenicity and engagement and expansion of an HPV 6-specific cellular response, including cytotoxic T cells. The paper also showed that VIO’s immunotherapy allowed two out of two patients who previously required approximately two surgeries per year for several years to manage this disease to delay the need for surgery to a robust degree; one patient was able to delay surgery for over a year and a half (584 days surgery-free) and a second remained surgery-free for over two and a half years (over 915 days surgery-free).